Phase 3
Recruiting

Ziltivekimab (IL-6 inhibitor)

Sponsored by AstraZeneca
Timeline
Study Dates
Start Date
June 2022
Est. Completion
June 2027
Enrollment Target
6000 participants
Status
Recruiting
Study Design
Primary Endpoint
MACE composite in high-risk patients with elevated hsCRP and chronic kidney disease
⚠ No ClinicalTrials.gov registry ID found for this program. This trial was announced but no registered study has been identified. CelluTarget flags this distinction rather than treating announced and registered trials as equivalent.
Related Treatment
Treatment Being Studied
Ziltivekimab (IL-6 inhibitor)